ReviewInternational journal of molecular sciences2023
Gut Microbiota Composition and Cardiovascular Disease: A Potential New Therapeutic Target?
Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- The impact of dietary patterns on gut microbiota for the primary and secondary prevention of cardiovascular disease: a systematic review.Nutrition journal · 2025Pooled it
- Pooled it
- Gut Microbiota: Cardiovascular Disease Prevention and Targeted Therapies.Biomedicines · 2026Review
- Review
- Multiomics: the intersection of personalized nutrition in cardiometabolic diseases.Journal of translational medicine · 2026Review
- The Gut-Heart Axis: A Comprehensive Review of Microbiota's Role in Cardiovascular Health and Disease and Emerging Therapeutic Strategies.Cardiology research and practice · 2026Review
- Modulation of gut microFLORA with rifaximin to reduce high platelet reactivity in post-ACS patients on ticagrelor: rationale and design of the FLORA-ACS study.Cardiology journal · 2026Article
- Correlation Between Dysbiosis and Atrial Fibrillation: What's New?International journal of molecular sciences · 2025Review
- Review
- Preliminary Evidence for Sex-Specific Trends in Probiotic Modulation of Gut Saccharibacteria in Familial Mediterranean Fever Patients: Effects ofInternational journal of molecular sciences · 2025Article
- Microbiome and cardiovascular health unexplored frontiers in precision cardiology: a narrative review.Annals of medicine and surgery (2012) · 2025Review
- Intestinal Microbiota in Early Life: Latest Findings Regarding the Role of Probiotics as a Treatment Approach for Dysbiosis.Nutrients · 2025Review
- Exploring hypertension-linked diseases: a comprehensive review of innovative drug combinations with enhanced therapeutic potential.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Boosting Immunity Through Nutrition and Gut Health: A Narrative Review on Managing Allergies and Multimorbidity.Nutrients · 2025Review
- Non-Traditional Cardiovascular Risk Factors: Tailored Assessment and Clinical Implications.Journal of cardiovascular development and disease · 2025Review
- Metagenomic Sequencing Combined with Metabolomics to Explore Gut Microbiota and Metabolic Changes in Mice with Acute Myocardial Infarction and the Potential Mechanism of Allicin.Drug design, development and therapy · 2025Article
- Integrated Microbiome and Metabolome Analysis Reveals Correlations Between Gut Microbiota Components and Metabolic Profiles in Mice With Mitoxantrone-Induced Cardiotoxicity.Drug design, development and therapy · 2025Article
- The role of the gut microbiota in the onset and progression of heart failure: insights into epigenetic mechanisms and aging.Clinical epigenetics · 2024Review
- A Metabolomic Approach to Unexplained Syncope.Biomedicines · 2024Article
- Intestinal Insights: The Gut Microbiome's Role in Atherosclerotic Disease: A Narrative Review.Microorganisms · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A great deal of evidence has revealed an important link between gut microbiota and the heart. In particular, the gut microbiota plays a key role in the onset of cardiovascular (CV) disease, including heart failure (HF). In HF, splanchnic hypoperfusion causes intestinal ischemia resulting in the translocation of bacteria and their metabolites into the blood circulation. Among these metabolites, the most important is Trimethylamine N-Oxide (TMAO), which is responsible, through various mechanisms, for pathological processes in different organs and tissues. In this review, we summarise the complex interaction between gut microbiota and CV disease, particularly with respect to HF, and the possible strategies for influencing its composition and function. Finally, we highlight the potential role of TMAO as a novel prognostic marker and a new therapeutic target for HF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.